https://www.eurekalert.org/pub_releases/2021-01/wcm-nmt012221.php
News Release 22-Jan-2021
Weill Cornell Medicine
Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites. This is the first time a maintenance treatment for AML has shown such a strong benefit for patients, and it is already being adopted as part of standard care.
The results, which were published Dec. 24 in the New England Journal of Medicine, led to the U.S. Food and Drug Administration's approval in September 2020 of oral azacitidine, known by the trade name Onureg, as a maintenance therapy for AML.
•••••
"We are especially gratified that the drug is very well-tolerated, so that quality of life is not compromised."
•••••
Side effects with oral azacitidine that were somewhat more common in the
treatment group included vomiting, low white blood cell counts, and
infections, but these were generally considered manageable and did not
result in treatment discontinuation.
•••••
No comments:
Post a Comment